Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 51 of 6351
-
New hope for Platinum-Resistant ovarian cancer: BL-M07D1 enters phase 3 trial
Disease control Not yet recruitingThis trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-expressing platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Womb transplant trial offers hope for women with uterine infertility
Disease control Recruiting nowOur study will explore the feasibility of initiating a deceased donor uterine transplant program in addition to the existing living donor IRB at BWH. Using the template established by teams around the world, we will identify emotionally and socially stable females of reproductiv…
Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Womb transplant trial offers hope for women born without a uterus
Disease control Recruiting nowThis study will examine the feasibility of initiating a uterine transplant program for Absolute Uterine Factor Infertility (AUFI) at Brigham and Women's Hospital. The investigators plan to screen 30 patients with a goal of enrolling 10 patients. (5 donors and 5 recipients) After …
Phase 2/3 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New triple therapy aims to reverse early diabetes
Disease control Not yet recruitingThe goal of this clinical trial is to learn the efficacy of combination therapy with tirzepatide, empagliflozin and pioglitazone versus standard therapy in newly diagnosed type 2 diabetes. The main objectives to achieve are: 1. To compare efficacy of the triple combination thera…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread
Disease control Not yet recruitingThis phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treatment of hormone-sensitive prostate cancer has spread to a limited number of anatomic sites at the time of initial diagnos…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Not yet recruitingThis is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy
Phase 1 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Combination therapy aims to wipe out High-Risk prostate cancer before surgery
Disease control Not yet recruitingThe goal of this clinical trial is to explore the efficacy and safety of darolutamide combined with 177Lu-PSMA-617 in treating high-risk localized prostate cancer patients who are scheduled to undergo radical prostatectomy. The main questions it aims to answer are: Does this com…
Phase 4 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Stroke drug given during ambulance ride could boost recovery
Disease control Not yet recruitingThis is a multicenter, randomized, double-blind, placebo-controlled clinical trial (SLEDAIS) involving 1,040 patients with acute ischemic stroke (AIS) who require inter-hospital transfer for potential endovascular therapy. The study aims to evaluate the efficacy and safety of sub…
Phase 4 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Immunotherapy boosts chemo against tough childhood cancer
Disease control Not yet recruitingThis clinical trial investigates the safety, side effects, and effectiveness of combining an immunotherapy drug called dinutuximab-beta with standard induction chemotherapy for patients newly diagnosed with high-risk neuroblastoma. Dinutuximab-beta is an antibody designed to targ…
Phase 1 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug cocktail aims to outsmart untreatable bile duct cancer
Disease control Not yet recruitingThis is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and cisplatin (GEMCIS) in combination with tislelizumab…
Phase 3 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug cocktail aims to wipe out bladder cancer before surgery
Disease control Recruiting nowObjectives: To evaluate the non-inferiority of disitamab vedotin plus gemcitabine versus disitamab vedotin plus toripalimab in terms of the pathological complete response (pCR) rate as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). This study is designed to evalu…
Phase 3 • Sponsor: Zhiquan Hu • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Experimental drug aims for functional cure in hepatitis b
Disease control Not yet recruitingBepirovirsen Liver Biopsy study is a single centre open label phase II study to examine the antiviral and immunological effects of bepirovirsen in CHB patients both treated and untreated with HBsAg\<1000 IU/ml
Phase 2 • Sponsor: National University Health System, Singapore • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Particle beam and immune therapy join forces against cervical cancer
Disease control Recruiting nowThis study explores the therapeutic effect of carbon ion radiotherapy plus immunotherapy and chemotherapy for locally advanced cervical cancer.
Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug aims to outsmart Chemotherapy-Resistant ovarian cancer
Disease control Not yet recruitingThis is a randomized, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of SYS6043 versus investigator's choice chemotherapy in participants with platinum-resistant ovarian cancer, primary peritoneal, or fallopian tube cancer.
Phase 3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental drug aims to tackle both obesity and knee arthritis
Disease control Not yet recruitingThe study is being conducted to evaluate the efficacy and safety of Ribupatide Injection in participants with obesity and knee osteoarthritis, and to explore its improvement on knee joint structure.
Phase 3 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New Four-Drug cocktail aims to wipe out Hard-to-Treat myeloma
Disease control Not yet recruitingThe goal of this study is to evaluate treatment of newly diagnosed multiple myeloma patients with t(11;14) suitable for transplantation using the SonKRd regimen, consisting of Sodium Thiotepa, Caffizotide, Lenalidomide, and Dexamethasone. Main objectives is to evaluate the MRD ne…
Phase 4 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Bladder cancer breakthrough? new combo aims to save the bladder
Disease control Recruiting nowThis is a multicenter, prospective, open-label, Phase II, four-arm parallel study evaluating the efficacy and safety of different sensitization strategies combined with disitamab vedotin and toripalimab in patients with HER2-positive muscle-invasive urothelial carcinoma of the bl…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Your genes could hold the key to better depression treatment
Diagnosis Not yet recruitingBackground: The clinical management of major depressive disorder (MDD) is hampered by the lack of objective biomarkers and high inter-individual variability in drug response, with conventional antidepressants achieving only a 50% response rate. Objective and Design: This prospec…
Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
Can a new daily pill lift the fog of depression?
Disease control Not yet recruitingThis trial includes a short-term study and a long-term study. The short-term study is a multicenter, randomized, double-blind, placebo-controlled parallel-group study with a 6-week duration. The long-term study is a multicenter, open-label, single-arm study with a maximum duratio…
Phase 3 • Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could some breast cancer patients skip radiation entirely?
Disease control Recruiting nowThis is a prospective, multicenter, randomized, open-label, phase III non-inferiority trial designed to evaluate whether omission of postoperative radiotherapy is clinically acceptable in patients with low- and intermediate-risk ductal carcinoma in situ (DCIS) following breast-co…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC